

## Special Issue

# Alternatives in the Post-antibiotic Era: Bacteriophages

### Message from the Guest Editors

Antibiotic resistance is a global problem. So the search for new, alternative solutions is extremely important. Phage-based therapeutic approaches are very suitable as part of an attractive alternative strategy to combat antibiotic resistance. Therefore, the topics of this Special Issue will cover any phage-based method to prevent, control or treat antibiotic-resistant bacteria, especially human pathogenic bacteria. This issue welcomes various types of submissions, such as original research papers, short communications, reviews, and case reports etc. Potential topics include:

- phage therapy;
- characteristics and applications of new phages;
- prophylactic/biocontrol applications of phages;
- the use of phage-antibiotic combinations;
- phage-derived antimicrobial peptides, depolymerase, endolysins, holin and their engineered derivatives etc.;
- exploitation of phage resistance mechanisms;
- phage bioengineering or CRISPR-Cas-based engineering to obtain suitable phage for applying treatment in antibiotic-resistant bacteria.

---

### Guest Editors

Prof. Dr. Nien-Tsung Lin

Department of Microbiology and Immunology, School of Medicine, Tzu Chi University, Hualien 97004, Taiwan

Prof. Dr. Ling-Chun Lin

Department of Microbiology and Immunology, School of Medicine, Tzu Chi University, Hualien, Taiwan

---

### Deadline for manuscript submissions

closed (31 March 2022)



## Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.3  
CiteScore 7.3  
Indexed in PubMed



[mdpi.com/si/94959](https://mdpi.com/si/94959)

*Antibiotics*

MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.3  
CiteScore 7.3  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1  
(General Pharmacology, Toxicology and Pharmaceutics)